Healthcare can be complicated.
Your cardiology news shouldn’t be.
Join thousands of cardiology leaders today.
Cardiology October 24, 2024
The State of Cardiology Employment October 24, 2024
MedAxiom released its 12th annual Cardiovascular Provider Compensation and Production Report, providing an in-depth look at the current state of working in cardiology. The massive 60-page report (n=5,663 providers, 202 programs, 2023 data) outlined four notable employment trends… Rising PE Ownership – Nearly 50% of surveyed private practice groups were also part of a private […]
Pharmaceuticals October 21, 2024
Exploring Semaglutide’s Cardiovascular Impact October 21, 2024
JACC took a deep dive into semaglutide’s cardiovascular impact, publishing six analyses of three separate trials that delivered new insights into the drug’s heart benefits, while raising even more questions about how it works. One STEP-HFpEF trial analysis showed that patients with obesity-related HFpEF on semaglutide achieved cardiac remodeling benefits beyond the impact of weight […]
Atrial Fibrillation October 17, 2024
InCarda Gets Mixed Results in AFib Inhaler Trial October 17, 2024
AFib inhalers took a small step closer to becoming a reality after InCarda Therapeutics’ Phase 3 RESTORE-1 trial showed that its FlecIH-103 inhaled flecainide formulation can rapidly convert paroxysmal AFib to normal sinus rhythm. However, challenges with the study suggest that InCarda has more work to do in order to achieve this reality. The new […]
Cholesterol Reduction October 10, 2024
AstraZeneca Adds Lp(a) Candidate with CSPC Licensing Move October 10, 2024
AstraZeneca expanded its cardiovascular pipeline this week, signing an exclusive license agreement for CSPC Pharmaceutical Group’s Lp(a) disruptor candidate, YS2302018. The deal comes with a $100M upfront investment that could reach $1.92B depending on further milestones. CSPC’s YS2302018 addresses a sizable target market, noting that nearly 70% of patients with CVD aren’t meeting guideline-directed LDL-C […]
More Stories
Heart Failure October 7, 2024
Finerenone’s Early Heart Failure Impact October 7, 2024
The FINEARTS-HF trial already showed that Bayer’s nsMRA finerenone (Kerendia) has the potential to slash mortality and event rates in HFpEF and HFmrEF patients, and new analysis suggests that its impact could be even greater if used earlier. The original FINEARTS-HF trial presented at ESC 2024 saw finerenone drive a 16% reduction in cardiovascular death […]
Heart Failure October 3, 2024
EMBARK-HFpEF Trial Flexes Mavacamten’s HF Potential October 3, 2024
A new HFpEF treatment might be on the horizon, after results from the EMBARK-HFpEF trial showed that BMS’ hypertrophic cardiomyopathy treatment, mavacamten (Camzyos), safely improved key HFpEF symptoms and biomarkers. To test mavacamten’s HFpEF potential, the open-label Phase 2a EMBARK-HFpEF trial treated 30 HFpEF patients with mavacamten (avg age 76, NYHA Class II & III, […]
Preventive Cardiology September 30, 2024
Cancer’s CVD Risks and SGLT2is’ Preventative Potential September 30, 2024
Better treatments have led to improved cancer survival rates, but new research reveals increased cardiovascular complications in survivors. However, another new study offers hope, suggesting that heart medications like SGLT2 inhibitors may help prevent cancer-related heart disease. A new Cancer Journal study showed that older cancer survivors have far higher rates of cardiovascular events than […]
Heart Failure September 26, 2024
Windtree’s Istaroxime Scores in Cardiogenic Shock Trial September 26, 2024
Windtree Therapeutics’ istaroxime appears to have scored in its latest Phase 2b trial, showing that the steroidal drug significantly improves systolic blood pressure in cardiogenic shock patients. The Phase 2b SEISMiC extension trial evaluated istaroxime infusions for up to 60 hours in patients with early-stage cardiogenic shock, measuring its impact during the first 96 hours […]
Pharmaceuticals September 23, 2024
Edgewise Therapeutics’ EDG-7500 Emerges as New HCM Contender September 23, 2024
A new HCM competitor emerged last week, after Edgewise Therapeutics’ EDG-7500 showed strong evidence of its safety and efficacy in a pair of early-stage trials. Edgewise tested EDG-7500 in a Phase 1 trial to confirm the drug’s side effects, and an early part of a Phase 2 trial to measure EDG-7500’s impact on key oHCM […]
Surgeries & Interventions September 19, 2024
Questioning PCI’s Left Ventricular Dysfunction Effect September 19, 2024
New analysis of the REVIVED-BCIS2 trial adds more evidence that PCI has limited impact in patients with left ventricular dysfunction, even when you include quality of life and overall health status. The secondary analysis of the REVIVED-BCIS2 trial examined outcomes from 700 patients with severe ischemic left ventricular systolic dysfunction (median age: 70yrs; mean LVEF: […]
Hypertension September 16, 2024
America’s Hypertension Awareness and Control Problem September 16, 2024
Nearly half of American adults have hypertension, and a new JAMA study reveals that the vast majority of them don’t have their blood pressure under control, while most don’t even know they have the disease. To better understand our hypertension control challenges, a CDC team analyzed 2017-2020 NHANES survey data featuring 7,328 U.S. adults (3,954 […]
Atrial Fibrillation September 12, 2024
AFib Might Be Far More Common Than We Think September 12, 2024
A JACC study suggests that atrial fibrillation is far more prevalent than many previously thought, estimating that nearly one in 20 American adults have been diagnosed with the disease. UCSF researchers analyzed medical records from 29M adults who received hospital-based care in California from 2005 to 2019 (51yr avg. age, 54% women, 50% White), finding […]
Pharmaceuticals September 9, 2024
Questioning Beta-Blocker Interruption After Heart Attack September 9, 2024
Results from the ABYSS trial surprised many at ESC 2024, finding that patients who continue beta-blocker therapy after heart attacks have better long-term outcomes than patients who stop taking the drugs, and they don’t experience the quality of life downsides that some might expect.
Atrial Fibrillation September 5, 2024
Burn the Ships? What OCEANIC-AF Means for Asundexian and Factor XI September 5, 2024
Nearly a year after Bayer halted its OCEANIC-AF trial, the study’s ESC 2024 presentation revealed new insights into asundexian’s AFib stroke-prevention challenges and what they might mean for Factor XI inhibitors.
Pharmaceuticals September 3, 2024
Alylam’s Vutrisiran Shines in HELIOS-B Trial September 3, 2024
Alylam’s vutrisiran dominated early ESC 2024 headlines and conversations, after full results from the Phase 3 HELIOS-B trial highlighted its significant impact on transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
Cholesterol Reduction August 29, 2024
Novartis Leqvio’s Case for Broader ASCVD Prevention August 29, 2024
Novartis’ Leqvio took a major step towards establishing itself as an LDL-C monotherapy, after topline results from the V-MONO study revealed significant LDL-C reductions in patients with low or moderate ASCVD risks.
Preventive Cardiology August 26, 2024
Tirzepatide’s Prediabetes and Hypertension Impact August 26, 2024
It looks like we might be able to add prediabetes and hypertension to the growing list of conditions that Eli Lilly’s “weight loss drug” tirzepatide is able to treat, after new analysis of the SURMOUNT-1 trial showed significant reductions in blood pressure and diabetes progression.
Cardiology Business August 22, 2024
J&J Expands Into Interventional HF Treatments With V-Wave Acquisition August 22, 2024
Johnson & Johnson expanded deeper into heart failure and interventional cardiology this week, acquiring interatrial shunt-maker V-Wave for $600M upfront and up to $1.7B with certain milestones.
Pharmaceuticals August 19, 2024
Medicare Drug Cuts Target CVD Meds, Drive Debates August 19, 2024
The White House finally unveiled its negotiated Medicare drug prices, bringing 38%-76% reductions to the first 10 drugs, while drawing mixed industry reactions.
Heart Failure August 15, 2024
Rivus HU6 Shows Obesity-HFpEF Potential August 15, 2024
Rivus Pharmaceuticals’ HU6 is showing promise as a future obesity-related HFpEF treatment, after topline results from its Phase 2a HuMAIN trial revealed valuable weight, symptom, and cardiometabolic improvements - without the risk of muscle loss.
Artificial Intelligence August 12, 2024
Cardiology AI Clearances Growing, Diversifying August 12, 2024
The FDA updated its healthcare AI database last week, increasing its list of AI-enabled clearances to a whopping 950 medical devices, while highlighting some interesting trends in cardiovascular AI.
Heart Failure August 8, 2024
Bayer’s Kerendia Could Become First nsMRA Heart Failure Treatment August 8, 2024
Bayer’s nsMRA finerenone (Kerendia) might be on track to becoming a key heart failure treatment, after topline results from the FINEARTS-HF trial showed that finerenone significantly reduces cardiovascular death and HF events among patients with mildly reduced or preserved ejection fraction.
